润都股份：硫酸氨基葡萄糖氯化钠复盐获得化学原料药上市申请批准通知书

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of glucosamine sulfate sodium chloride compound, which is intended for the treatment of primary and secondary osteoarthritis, enhancing the company's product portfolio and market competitiveness, positively impacting future operational performance [1] Company Summary - The approved drug will enrich the company's product categories, which is beneficial for improving market competitiveness [1] - The approval is expected to have a positive effect on the company's future operating performance [1] Industry Summary - The market sales of the newly approved drug may be influenced by various uncertain factors, including policy environment and market changes [1]